Show simple item record

dc.contributor.authorSeguí, J.
dc.contributor.authorLópez-Muñoz, F.
dc.contributor.authorÁlamo González, C
dc.contributor.authorCamarasa, X.
dc.contributor.authorGarcía-García, P.
dc.contributor.authorPardo, A.
dc.date.accessioned2018-06-06T10:57:41Z
dc.date.available2018-06-06T10:57:41Z
dc.date.issued2010
dc.identifier.issn0271-0749
dc.identifier.issn0964704X
dc.identifier.urihttp://hdl.handle.net/20.500.12020/721
dc.description.abstractThe efficacy of the combination therapy with two antidepressants from different pharmacological families in patients with treatment-resistant depression has been reported in multiple studies. In this prospective 12-weeks open-label study, we assessed the effectiveness of the addition of reboxetine to 79 depressive outpatients diagnosed with major depressive disorder (MDD) according to the DSM-IV criteria who had previously not responded, or had done so only in a partial way, over 8 weeks of conventional treatment, in monotherapy, with duloxetine. Efficacy was assessed using the 21-item Hamilton Depression Rating Scale (HDRS) and the Clinical Global Impression-Improvement (CGI-I). Safety was evaluated by recording spontaneously reported adverse events. Data were analysed on an intent-to-treat basis, using the last-observation-carried-forward method. Mean HDRS reduction was 65.5% (P < 0.0001). The percentages of responders (>or=50% reduction in HDRS) and patients considered benefiting from complete remission (HDRS <or= 10 points) at week 12 were 76% and 69.3%, respectively. By the end of the treatment, the score of CGI-I decreased 68.5% (P < 0.0001). Percentage of patient improving (CGI < 4 points) was 95.8%. The most common non-serious adverse events were dry mouth, increased sweating, constipation and difficulty passing urine. The results of this study suggest that the combination strategy with reboxetine may be an effective and well-tolerated tool in duloxetine-resistant patients.es
dc.language.isoenes
dc.publisherTaylor & Francises
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.titleEffects of adjunctive reboxetine in patients with duloxetineresistant depression: A 12-week prospective studyes
dc.typearticlees
dc.identifier.doi10.1177/0269881109102641
dc.issue.number24es
dc.journal.titleJournal of Psychopharmacologyes
dc.page.initial1201es
dc.page.final1207es
dc.rights.accessRightsopenAccesses
dc.subject.areaPsicologíaes
dc.subject.keywordFarmacologíaes
dc.subject.keywordNeurologíaes
dc.subject.keywordNeurocienciaes
dc.subject.keywordReboxetinaes
dc.subject.keywordDepresiónes
dc.subject.unesco3209.09 Psicofarmacologíaes
dc.subject.unesco3209 Farmacologíaes


Files in this item

File/sSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 Internacional